课题基金 / 基金详情

项目摘要

项目成果

THOMAS F GAJEWSKI的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The specific recognition of tumor antigens by CD8+ T cells, and the binding of monoclonal antibodies to tumor targets represent the main effector mechanisms for immune-mediated tumor rejection. The exquisite specificity of these interactions has earned cancer immunotherapy the designation as a targeted therapy. Excitement in this area was reinforced by the FDA approval of several monoclonal antibodies, such as Herceptin for breast cancer and Rituxan for lymphoma, as well as two cytokines, interleukin-2 and interferon-a, for the treatment of melanoma and kidney cancer. In addition, allogeneic bone marrow transplantation has therapeutic effects through a cell-mediated graft-versus-tumor immune response. However, the efficacy of these therapies is still suboptimal. Improving upon the effectiveness of current agents, developing new immunotherapeutic interventions (such as anti-cancer vaccines), and elucidating the mechanism of success versus failure of investigational treatments, all require careful monitoring of scientific endpoints. The main purpose of the Human Immunologic Monitoring Facility is to perform such assays in the context of clinical trials in cancer patients. As such, it serves as a specialized laboratory for evaluating pharmacodynamic parameters in response to agents or interventions that impact on immune cells. This service enables a range of clinical cancer researchers, who don't necessarily have laboratory expertise themselves, to measure immunologic endpoints in participating study subjects. The Facility also monitors biologic effects of other pharmacologic agents (such as signal transduction inhibitors) using lymphocytes or other hematopoietic cells as a surrogate tissue. Finally, the technologists of our Core interface with the cGMP Facility to carry out the preparation of clinical-grade products, such as cancer vaccines, for administration to patients. Thus, this Facility lies at the heart of our clinical/translational effort in cancer immunotherapy, and is vital for the scientific investigation of additional novel agents.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Overcoming resistance to anti-PD1 immunotherapy
  • 批准号:
    10057358
  • 项目类别:
  • 资助金额:
    $94.33万
  • 财政年份:
    2016
  • 负责人:
    THOMAS F GAJEWSKI
  • 依托单位:
Overcoming resistance to anti-PD1 immunotherapy
  • 批准号:
    10547757
  • 项目类别:
  • 资助金额:
    $92.71万
  • 财政年份:
    2016
  • 负责人:
    THOMAS F GAJEWSKI
  • 依托单位:
Overcoming resistance to anti-PD1 immunotherapy
  • 批准号:
    10737852
  • 项目类别:
  • 资助金额:
    $97.02万
  • 财政年份:
    2016
  • 负责人:
    THOMAS F GAJEWSKI
  • 依托单位:
Overcoming resistance to anti-PD1 immunotherapy
  • 批准号:
    9186858
  • 项目类别:
  • 资助金额:
    $94.12万
  • 财政年份:
    2016
  • 负责人:
    THOMAS F GAJEWSKI
  • 依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
  • 批准号:
    2021JJ40433
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2021
  • 负责人:
    孙磊
  • 依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
  • 批准号:
    32001603
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    段真珍
  • 依托单位:
AREA国际经济模型的移植.改进和应用
  • 批准号:
    18870435
  • 项目类别:
    面上项目
  • 资助金额:
    2.0万元
  • 批准年份:
    1988
  • 负责人:
    史树中
  • 依托单位: